Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (functional) | = 0.0054 ug ml-1 | Concentration of compound that reduces the viability of mock-infected MT-4 cells by 50% | ChEMBL. | 15481992 |
CC50 (functional) | = 0.0054 ug ml-1 | Concentration of compound that reduces the viability of mock-infected MT-4 cells by 50% | ChEMBL. | 15481992 |
EC50 (functional) | = 0.0011 ug ml-1 | Concentration required for protection of MT-4 cells from HIV-2 (ROD) induced cytopathogenicity in MTT assay | ChEMBL. | 15481992 |
EC50 (functional) | = 0.0011 ug ml-1 | Concentration required for protection of MT-4 cells from HIV-2 (ROD) induced cytopathogenicity in MTT assay | ChEMBL. | 15481992 |
EC50 (functional) | > 0.0054 ug ml-1 | Concentration required for protection of MT-4 cells from HIV-1 (IIIB) induced cytopathogenicity in MTT assay | ChEMBL. | 15481992 |
EC50 (functional) | > 0.0054 ug ml-1 | Concentration required for protection of MT-4 cells from HIV-1 (IIIB) induced cytopathogenicity in MTT assay | ChEMBL. | 15481992 |
Protection (functional) | < 30 % | Maximum protection (%) of MT-4 cells from HIV-1 (IIIB) induced cytopathogenicity; value ranges from 25-30% | ChEMBL. | 15481992 |
Protection (functional) | < 30 % | Maximum protection (%) of MT-4 cells from HIV-1 (IIIB) induced cytopathogenicity; value ranges from 25-30% | ChEMBL. | 15481992 |
Protection (functional) | < 81 % | Maximum protection (%) of MT-4 cells from HIV-2 (ROD) induced cytopathogenicity; value ranges from 51-81% | ChEMBL. | 15481992 |
Protection (functional) | < 81 % | Maximum protection (%) of MT-4 cells from HIV-2 (ROD) induced cytopathogenicity; value ranges from 51-81% | ChEMBL. | 15481992 |
Selectivity index (functional) | < 1 | Selectivity index of the compound towards HIV-1 (IIIB) in MT-4 cells | ChEMBL. | 15481992 |
Selectivity index (functional) | = 5.1 | Selectivity index of the compound towards HIV-2 (ROD) in MT-4 cells | ChEMBL. | 15481992 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.